Production of a genetically engineered inhibin vaccine

By Geary T.W.   Reeves J.J.  

Vaccine, Vol. 14, Iss. 13, 1996-09 ,pp. : 1273-1279

Elsevier

Access to resources Recommend Favorite

Immunogenicity studies with a genetically engineered hexavalent PorA and a wild-type meningococcal group B outer membrane vesicle vaccine in infant cynomolgus monkeys

By Rouppe van der Voort E.   Schuller M.   Holst J.   de Vries P.   van der Ley P.   van den Dobbelsteen G.   Poolman J.  

Vaccine, Vol. 18, Iss. 14, 2000-02 ,pp. : 1334-1343

Elsevier

Access to resources Recommend Favorite

Experimental quantification of transmission of genetically engineered pseudorabies virus

By Mulder W.A.M.   De Jong M.C.M.   Priem J.   Bouma A.   Pol J.M.A.   Kimman T.G.  

Vaccine, Vol. 13, Iss. 18, 1995-01 ,pp. : 1763-1769

Elsevier

Access to resources Recommend Favorite

Enhanced activation of rhesus T cells by vectors encoding a triad of costimulatory molecules (B7-1, ICAM-1, LFA-3)

By Shankar P.   Schlom J.   Hodge J.W.  

Vaccine, Vol. 20, Iss. 5, 2001-12 ,pp. : 744-755

Elsevier

Access to resources Recommend Favorite

Augmentation of cell-mediated immunotherapy against herpes simplex virus by interleukins: comparison of in vivo effects of IL-2 and IL-7 on adoptively transferred T cells

By Wiryana P.   Bui T.   Faltynek C.R.   Ho R.J.Y.  

Vaccine, Vol. 15, Iss. 5, 1997-04 ,pp. : 561-563

Elsevier

Access to resources Recommend Favorite